Cellectis SA (CLLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cellectis SA (CLLS) has a cash flow conversion efficiency ratio of -0.260x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.56 Million) by net assets ($59.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cellectis SA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Cellectis SA - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Cellectis SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cellectis SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellectis SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Supezet Engineering Technology Corp Ltd
SHG:688121
|
-0.016x |
|
Bin Chuan Enterprise Co Ltd
TWO:1569
|
-0.024x |
|
Medeon Biodesign
TWO:6499
|
-0.118x |
|
Exotic Food Public Company Limited
BK:XO
|
0.107x |
|
Laboratorio Reig Jofre S.A
MC:RJF
|
0.052x |
|
Wireless Power Amplifier Module Inc
KQ:332570
|
0.099x |
|
SilverBox Corp IV
NYSE:SBXD
|
-0.001x |
|
EVI Industries Inc
NYSE MKT:EVI
|
0.007x |
Annual Cash Flow Conversion Efficiency for Cellectis SA (2007–2025)
The table below shows the annual cash flow conversion efficiency of Cellectis SA from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Cellectis SA stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $75.90 Million | $-40.14 Million | -0.529x | -413.49% |
| 2024-12-31 | $131.03 Million | $22.10 Million | 0.169x | +157.73% |
| 2023-12-31 | $84.69 Million | $-24.75 Million | -0.292x | +57.92% |
| 2022-12-31 | $125.94 Million | $-87.44 Million | -0.694x | -57.03% |
| 2021-12-31 | $236.47 Million | $-104.56 Million | -0.442x | -70.15% |
| 2020-12-31 | $308.85 Million | $-80.26 Million | -0.260x | -33.61% |
| 2019-12-31 | $355.47 Million | $-69.14 Million | -0.195x | -28.54% |
| 2018-12-31 | $450.27 Million | $-68.14 Million | -0.151x | +17.32% |
| 2017-12-31 | $285.90 Million | $-52.33 Million | -0.183x | -61.34% |
| 2016-12-31 | $274.05 Million | $-31.09 Million | -0.113x | -1024.12% |
| 2015-12-31 | $288.22 Million | $3.54 Million | 0.012x | -98.25% |
| 2014-12-31 | $72.39 Million | $50.74 Million | 0.701x | +118.19% |
| 2013-12-31 | $6.65 Million | $-25.63 Million | -3.854x | -1105.67% |
| 2012-12-31 | $81.69 Million | $-26.11 Million | -0.320x | +10.29% |
| 2011-12-31 | $37.02 Million | $-13.19 Million | -0.356x | +15.35% |
| 2010-12-31 | $50.13 Million | $-21.10 Million | -0.421x | -337.25% |
| 2009-12-31 | $73.22 Million | $-7.05 Million | -0.096x | -350.06% |
| 2008-12-31 | $46.21 Million | $1.78 Million | 0.038x | +129.82% |
| 2007-12-31 | $43.54 Million | $-5.62 Million | -0.129x | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more